The same dopamine modulation that quiets food noise is applied to substance craving
But facial changes are common enough that the American Academy of Dermatology says people taking Wegovy, Ozempic, Zepbound and other GLP-1 medications are likely to notice changes such as loss of facial fullness, sagging skin and a crepey texture
Nat Med 2023
GLP-1s Are Lowering the Percentage of Americans With Obesity According to the same poll, the percentage of adults with obesity has also dropped to 37 percent, down from a record high of 39.9 percent in 2022
This raises ethical concerns around drug prioritization and access
Mechanism of Action Triple receptor co-agonism: GLP-1R for appetite suppression and incretin effect, GIPR for improved insulin sensitivity, glucagon receptor for increased energy expenditure and hepatic fat oxidation addressing obesity through three distinct metabolic pathways simultaneously Target: GLP-1 receptor (GLP1R), GIP receptor (GIPR), Glucagon receptor (GCGR) Clinical trials demonstrate significant body weight reduction with sustained benefit Improves glycemic control and A1C levels in type 2 diabetes Associated with reduced cardiovascular events in high-risk patients Addresses multiple components of metabolic syndrome simultaneously These are commonly discussed research protocols not medical advice
